A detailed history of Northern Trust Corp transactions in Legend Biotech Corp stock. As of the latest transaction made, Northern Trust Corp holds 83,892 shares of LEGN stock, worth $2.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
83,892
Previous 83,912 0.02%
Holding current value
$2.75 Million
Previous $3.72 Million 10.01%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$43.55 - $59.88 $871 - $1,197
-20 Reduced 0.02%
83,892 $4.09 Million
Q2 2024

Aug 14, 2024

SELL
$39.5 - $57.22 $158 - $228
-4 Reduced -0.0%
83,912 $3.72 Million
Q1 2024

May 14, 2024

BUY
$55.06 - $69.99 $79,286 - $100,785
1,440 Added 1.75%
83,916 $4.71 Million
Q4 2023

Feb 13, 2024

SELL
$57.25 - $69.74 $3.4 Million - $4.14 Million
-59,421 Reduced 41.88%
82,476 $4.96 Million
Q3 2023

Nov 13, 2023

SELL
$63.16 - $76.5 $142,804 - $172,966
-2,261 Reduced 1.57%
141,897 $9.53 Million
Q2 2023

Aug 11, 2023

SELL
$46.28 - $75.01 $1.47 Million - $2.38 Million
-31,759 Reduced 18.05%
144,158 $9.95 Million
Q1 2023

May 15, 2023

BUY
$43.42 - $57.37 $2.88 Million - $3.8 Million
66,224 Added 60.37%
175,917 $8.48 Million
Q4 2022

Feb 13, 2023

BUY
$38.8 - $55.46 $30,613 - $43,757
789 Added 0.72%
109,693 $5.48 Million
Q3 2022

Nov 14, 2022

BUY
$38.15 - $57.1 $211,694 - $316,847
5,549 Added 5.37%
108,904 $4.44 Million
Q2 2022

Aug 12, 2022

BUY
$33.54 - $55.0 $295,554 - $484,660
8,812 Added 9.32%
103,355 $5.68 Million
Q1 2022

May 13, 2022

BUY
$31.02 - $48.18 $2.93 Million - $4.56 Million
94,543 New
94,543 $3.44 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $5.49B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.